Randomized controlled clinical study to evaluate the efficacy of Pama-Dadru-Vicharchikahar Lepa topically in the management of Vicharchika (eczema)

Abstract

Background: The worldwide prevalence of eczema ranges from 15% to 20%. The exact cause of eczema is unknown. The modern dermatology employs systemic and local administration of steroid for the management of eczema. Despite an initial response, maintenance therapies with the small dose of systemic and topical glucocorticoid usually produce hazardous ill effect. This study evaluates and compares the effect of both the systems of medicine to get safe and cost-effective treatment. Aim: The purpose of this study was to compare the therapeutic efficacy of Pama-Dadru-Vicharchikahar Lepa (PDVL) to mometasone furoate 0.1% in the treatment of Vicharchika. Materials and Methods: Patients who arrived to the OPD and IPD of the Department of Kayachikita, DMM Ayurved College, Yavatmal, possess Vicharchika’s classical signs and symptoms. In this study, 60 patients enrolled in two groups: 30 patients of group A treated with the local application of PDVL and similarly 30 patients of group B treated with the local application of mometasone furoate 0.1% ointment for 45 days with follow-up of 45 days. The data were compared: Wilcoxon signed rank test was used within each group, whereas the Mann–Whitney test was used between groups. Result: After 90 days of treatment with follow-up, it was found that in the trial group, PDVL, average % relief was 83.86%. In the control group, mometasone furoate 0.1%, average % relief was 79.69%. PDVL was found effective on % relief, safe, easy to administer, and cost-effective. Conclusion: The local application of PDVL is effective than mometasone furoate 0.1% in the management of Vicharchika to reduce Shyava Varna, whereas the local application of PDVL is not effective than mometasone furoate 0.1% topically in the management of Vicharchika to reduce Kandu, Pidika, Rukshata, Strava, Rajyo, Lohit Varna, Ruja, and Eczema Area And Severity Index score. CTRI Number: CTRI/2020/06/025982